Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases2025-05-090%External coverage
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program2025-04-1015%External coverage
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases2025-03-3115%External coverage
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders2024-11-2115%External coverage
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes2024-11-0138%External coverage
Conduit Pharmaceuticals Granted Patent Approval For Autoimmune Diseases Treatment2024-07-160%External coverage
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases2024-07-1615%External coverage
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q1 20242024-05-1523%External coverage